King's Commercialisation Institute supports and accelerates innovation and commercialisation of life science research carried out by researchers and investigators in King's College London and King's Health Partners.The Institute has both outward and inward facing roles.
Every year the Commercialisation Institute conducts a peer reviewed commercial triage across its entire research project portfolio arising from over 1,000 researchers to identify the most compelling projects for commercial translation and investment. Peer review is obtained from industrial, investor and senior research leaders to ensure appropriate rigour and diversity of insights in the assessments.
The Institute then works with each of the selected projects to further them to a point of maturity that is ripe for investment.Therefore, the Commercialisation Institute aims to provide investors with pre-qualified investment opportunities. By this approach the Institute can more effectively secure commercialisation of its research and the delivery of benefits for patients, investors and society in general.
Advantages of the King’s approach:
Our high potential projects are selected based on a number of screening factors, including:
- A clear unmet clinical need addressed by the project
- A high utility value when clinically implemented
- Compelling market attractiveness based on size, growth and addressability
- A clear translational development path, preferably within two years to a transactable position
- One or more patent applications filed to provide protection for the technology
The Institute is staffed by seasoned individuals having significant industry and investor engagement experience and who understand an investor’s need for qualified opportunities.This enables the Institute to work with King’s researchers to better align a project so it is attractive for investment whilst being sensitive to investor requirements. The Institute aims to provide you with a more complete investment ready package than is traditionally provided by university technology transfer offices.
The Commercialisation Institute seeks to engage with venture capital, corporate and angel investors to assess the suitability of new biomedical technologies for industrial licensing or formation of spin out companies, where appropriate.